Wynn, Thomas A.
Pfizer Inc.,
United States
2025 Rank: 387
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 12 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 387 | 434 |
| Total Cites | 4599 | 4651 |
| H-index | 26 | 26 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 568 | 568 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 1863 | 1863 |
| Number of Single+First+Last Authored Papers | 121 | 121 |
| Total Cites to Single+First+Last Authored Papers | 3803 | 3811 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 3672 | 3705 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.26 |
| Self-Citation Percentage |
1.12%
|
|
Wynn, Thomas A.
Pfizer Inc.,
United States
2024 Rank: 304
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 11 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 304 | 345 |
| Total Cites | 4493 | 4554 |
| H-index | 27 | 27 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 650 | 650 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 1864 | 1867 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 3744 | 3763 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 3526 | 3558 |
| Ratio of Total Citations to Distinct Citing Papers | 1.27 | 1.28 |
| Self-Citation Percentage |
1.34%
|
|
Wynn, Thomas A.
Pfizer Inc.,
United States
2023 Rank: 300
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 12 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 300 | 322 |
| Total Cites | 4584 | 4656 |
| H-index | 27 | 28 |
| Hm-index | 14 | 14 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 610 | 610 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 1858 | 1859 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 3791 | 3815 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 3546 | 3589 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.30 |
| Self-Citation Percentage |
1.55%
|
|
Wynn, Thomas A.
National Institute of Allergy and Infectious Diseases (NIAID),
United States
2022 Rank: 231
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 11 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 231 | 261 |
| Total Cites | 4647 | 4727 |
| H-index | 28 | 28 |
| Hm-index | 14 | 14 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 670 | 670 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 1962 | 1963 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 3806 | 3820 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 3578 | 3619 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.31 |
| Self-Citation Percentage |
1.69%
|
|
Wynn, Thomas A.
Pfizer Inc.,
United States
2021 Rank: 289
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 10 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 289 | 318 |
| Total Cites | 6565 | 6691 |
| H-index | 32 | 32 |
| Hm-index | 16 | 16 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 964 | 964 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 2814 | 2818 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 5385 | 5419 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 5055 | 5129 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.30 |
| Self-Citation Percentage |
1.88%
|
|
Wynn, Thomas A.
National Institute of Allergy and Infectious Diseases,
United States
2020 Rank: 317
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 8 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 317 | 343 |
| Total Cites | 4686 | 4825 |
| H-index | 28 | 30 |
| Hm-index | 14 | 14 |
| Number of Single Authored Papers | 14 | 14 |
| Total Cites to Single Authored Papers | 713 | 716 |
| Number of Single+First Authored Papers | 38 | 38 |
| Total Cites to Single+First Authored Papers | 1903 | 1908 |
| Number of Single+First+Last Authored Papers | 113 | 113 |
| Total Cites to Single+First+Last Authored Papers | 3766 | 3813 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 3542 | 3618 |
| Ratio of Total Citations to Distinct Citing Papers | 1.32 | 1.33 |
| Self-Citation Percentage |
2.88%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.